Triglyceride-to-high-density-lipoprotein-cholesterol ratio is an index of heart disease mortality and of incidence of type 2 diabetes mellitus in men

Journal of Investigative Medicine

Volumn 62, Issue 2, 2014, Pages 345-349

  Vega, Gloria Lena ^a   Barlow, Carolyn E ^b   Grundy, Scott M ^a   Leonard, David ^b   DeFina, Laura F ^b  

^a UNIVERSITY OF TEXAS SOUTHWESTERN MEDICAL CENTER   (United States)

^b The Cooper Institute   (United States)

Author keywords

CHD mortality; CVD mortality; TG HDL C ratio

Indexed keywords

GLUCOSE; HIGH DENSITY LIPOPROTEIN CHOLESTEROL; TRIACYLGLYCEROL;

ADULT; AGED; ARTICLE; CARDIOMETABOLIC RISK; CARDIOVASCULAR MORTALITY; CARDIOVASCULAR PARAMETERS; CARDIOVASCULAR RISK; CHOLESTEROL BLOOD LEVEL; COHORT ANALYSIS; CONTROLLED STUDY; FOLLOW UP; GLUCOSE BLOOD LEVEL; HEART INDEX; HUMAN; HYPERGLYCEMIA; ICD-10; ICD-9; ISCHEMIC HEART DISEASE; MALE; METABOLIC SYNDROME X; MIDDLE AGED; NON INSULIN DEPENDENT DIABETES MELLITUS; PREDICTOR VARIABLE; SURVIVAL; TRIACYLGLYCEROL BLOOD LEVEL; TRIGLYCERIDE TO HIGH DENSITY LIPOPROTEIN CHOLESTEROL RATIO; VERY ELDERLY; YOUNG ADULT;

ADULT; AGED; AGED, 80 AND OVER; CHOLESTEROL, HDL; CORONARY DISEASE; DIABETES MELLITUS, TYPE 2; FEMALE; HUMANS; INCIDENCE; MALE; METABOLIC SYNDROME X; MIDDLE AGED; TRIGLYCERIDES; YOUNG ADULT;

EID: 84896795602     PISSN: 10815589     EISSN: 17088267     Source Type: Journal    
DOI: 10.2310/JIM.0000000000000044     Document Type: Article

References (21)

1. Hokanson JE, Austin MA. Plasma triglyceride level is a risk factor for cardiovascular disease independent of high-density lipoprotein cholesterol level: a meta-analysis of population-based prospective studies. J Cardiovasc Risk. 1996; 3(2): 213-219.
2. Sarwar N, Danesh J, Eiriksdottir G., et al. Triglycerides and the risk of coronary heart disease: 10,158 incident cases among 262,525 participants in 29 Western prospective studies [published online ahead of print December 26, 2006]. Circulation. 2007; 115(4): 450-458.
3. Ginsberg HN, Zhang YL, Hernandez-Ono A. Regulation of plasma triglycerides in insulin resistance and diabetes [review]. Arch Med Res. 2005; 36(3): 232-240.
4. Grundy SM, Cleeman JI, Daniels S.R., et al. American Heart Association; National Heart, Lung, and Blood Institute. Diagnosis and management of the metabolic syndrome: an American Heart Association/National Heart, Lung, and Blood Institute scientific statement [published online ahead of print September 12, 2005] [published correction appears in Circulation 2005; 112(17): e297, e298] [review]. Circulation. 2005; 112(17): 2735-2752.
5. Grundy SM. Hypertriglyceridemia, atherogenic dyslipidemia, and the metabolic syndrome [review]. Am J Cardiol. 1998; 81(4A): 18B-25B.
6. McLaughlin T, Reaven G, Abbasi F., et al. Is there a simple way to identify insulin-resistant individuals at increased risk of cardiovascular disease? Am J Cardiol. 2005; 96(3): 399-404.
7. Abbasi F, Reaven GM. Comparison of two methods using plasma triglyceride concentration as a surrogate estimate of insulin action in nondiabetic subjects: triglycerides × glucose versus triglyceride/high-density lipoprotein cholesterol [published online ahead of print May 31, 2011]. Metabolism. 2011; 60(12): 1673-1676.
8. Guerrero-Romero F., Simental-Mendia LE, Gonzalez-Ortiz M, et al. The product of triglycerides and glucose, a simple measure of insulin sensitivity. Comparison with the euglycemic-hyperinsulinemic clamp. J Clin Endocrinol Metab. 2010; 95(7): 3347-3351.
9. Blair SN, Kohl HW 3rd, Paffenbarger RS Jr, et al. Physical fitness and all-cause mortality. A prospective study of healthy men and women. JAMA. 1989; 262(17): 2395-2401.
10. DeFina LF, Vega GL, Leonard D, et al. Fasting glucose, obesity, and metabolic syndrome as predictors of type 2 diabetes: the Cooper Center Longitudinal Study. J Investig Med. 2012; 60(8): 1164-1168.
11. American Heart Association; National Heart, Lung, and Blood Institute, Grundy SM, Cleeman JI, Daniels SR, et al. Diagnosis and management of the metabolic syndrome. An American Heart Association/National Heart, Lung, and Blood Institute scientific statement. Executive summary. Cardiol Rev. 2005; 13(6): 322-327.
12. Grundy SM. Metabolic syndrome: a multiplex cardiovascular risk factor. J Clin Endocrinol Metab. 2007; 92: 399-404.
13. Church TS, Thompson AM, Katzmarzyk P.T., et al. Metabolic syndrome and diabetes, alone and in combination, as predictors of cardiovascular disease mortality among men. Diabetes Care. 2009; 32(7): 1289-1294.
14. Laws A, Reaven GM. Evidence for an independent relationship between insulin resistance and fasting plasma HDL-cholesterol, triglyceride and insulin concentrations. J Intern Med. 1992; 231(1): 25-30.
15. Salazar MR, Carbajal HA, Espeche W.G., et al. Comparison of the abilities of the plasma triglyceride/high-density lipoprotein cholesterol ratio and the metabolic syndrome to identify insulin resistance. Diab Vasc Dis Res. 2013; 10(4): 346-352.
16. Hanak V, Munoz J, Teague J., et al. Accuracy of the triglyceride to high-density lipoprotein cholesterol ratio for prediction of the low-density lipoprotein phenotype B. Am J Cardiol. 2004; 94(2): 219-222.
17. Dobiásová M, Frohlich J. The plasma parameter log (TG/HDL-C) as an atherogenic index: correlation with lipoprotein particle size and esterification rate in apoB-lipoprotein-depleted plasma (FER(HDL)). Clin Biochem. 2001; 34(7): 583-588.
18. Gaziano JM, Hennekens CH, O'Donnell CJ, et al. Fasting triglycerides, high-density lipoprotein, and risk of myocardial infarction. Circulation. 1997; 96(8): 2520-2525.
19. Salazar MR, Carbajal HA, Espeche W.G., et al. Identifying cardiovascular disease risk and outcome: use of the plasma triglyceride/high-density lipoprotein cholesterol concentration ratio versus metabolic syndrome criteria. J Intern Med. 2013; 273: 595-601.
20. Urbina EM, Khoury PR, McCoy C.E., et al. Triglyceride to HDL-C ratio and increased arterial stiffness in children, adolescents, and young adults. Pediatrics. 2013; 131(4): e1082-e1089.
21. Kannel WB, Vasan RS, Keyes M.J., et al. Usefulness of the triglyceride-high-density lipoprotein versus the cholesterol-high-density lipoprotein ratio for predicting insulin resistance and cardiometabolic risk (from the Framingham Offspring Cohort). Am J Cardiol. 2008; 101(4): 497-501.